PFE catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 20, 2026Sponsor estimate | NCT07821216Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims DataPfizer · Alopecia Areata | PFELead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
| Nov 30, 2026Sponsor estimate | NCT07494656A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in GermanyPfizer · ATTR-CM (Transthyretin Amyloid Cardiomyopathy) | PFELead | No phase registered | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Nov 20, 2026Sponsor estimateNo phase registeredNCT07821216Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims DataPfizer · Alopecia AreataActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2026Sponsor estimateNo phase registeredNCT07494656A Retrospective Observational Study of Epidemiology and Outcomes in Transthyretin Amyloid Cardiomyopathy in GermanyPfizer · ATTR-CM (Transthyretin Amyloid Cardiomyopathy)Active, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2, 2026Sponsor estimatePhase 3NCT07029711A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia AreataPfizer · Severe Alopecia AreataActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 4, 2026Sponsor estimateNo phase registeredNCT06622109A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six MonthsPfizer · Pneumococcal DiseaseActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 8, 2026Sponsor estimatePhase 2NCT07228390A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the...Pfizer · Hidradenitis SuppurativaActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 12, 2026Sponsor estimatePhase 1NCT06994897A Study to Learn How Different Amounts of the Study Medicine Called PF-07985631 Are Tolerated and Act in the Body of Healthy AdultsPfizer · HealthyActive, not recruitingPFELead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 6 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.